OptoSonics, Inc. is developing a new class of medical diagnostic 3D imaging instrumentation based on thermoacoustic and photoacoustic principles. The firm's initial product development aimed at breast cancer detection. As a developer of premier molecular imaging products, OptoSonics is pursuing important collaborations with leading medical schools and universities in an effort to significantly impact the fields of molecular biology, oncology, drug development and diagnostic medicine. OptoSonics' fundamentally new technology allows researchers and clinicians to "see" the very molecular basis of disease. For physicians, this revolutionary breakthrough offers a way to detect subtle alterations in the molecular structure of normal tissue as the disease progresses â long before such changes can be detected by other imaging technologies. The company is also involved in various research and development projects of thermoacoustic computed tomography and related technologies
